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Abstract
Epidermolysis bullosa (EB) is a group of hereditary skin diseases, or
genodermatoses, characterized by the formation of severe, chronic blisters with
painful and life-threatening complications. Despite the previous and ongoing
progress in the field, there are still no effective causative treatments for EB. The
treatment is limited to relieving symptoms, which—depending on disease severity
—may involve skin (blisters, poorly healing wounds caused by the slightest
mechanical stimuli, contractures, scarring, pseudosyndactyly) and internal organ
abnormalities (esophageal, pyloric, or duodenal atresia; renal failure; and hemato-
poietic abnormalities). The last decade saw a series of important discoveries that
paved the way for new treatment methods, including gene therapy, bone marrow
transplantation, cell therapy (allogenic fibroblasts, mesenchymal stem cells
[MSCs], and clinical use of induced pluripotent stem cells. Tissue engineering
experts are attempting to develop skin-like structures that can facilitate the process
of healing to promote skin reconstruction in injuries that are currently incurable.
However, this is incredibly challenging, due to the complex structure and the many
functions of the skin. Below, we characterize EB and present its potential treatment
methods. Despite the cure for EB being still out of reach, recent data from animal
models and initial clinical trials in humans have raised patients’, clinicians’, and
researchers’ expectations. Consequently, modifying the course of the disease and
improving the quality of life have become possible. Moreover, the conclusions
drawn based on EB treatment may considerably improve the treatment of other
genetic diseases.
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Epidermolysis Bullosa (EB) is a group of heterogeneous genetic conditions
(genodermatoses) characterized by skin fragility and blister formation. These blis-
ters, or bullae, may form spontaneously or as a result of slight mechanical injuries.
EB is estimated to occur in 1 person per 50,000 live births.
EB constitutes a group of conditions with diverse clinical courses. Depending on
the type of abnormalities in the specific genes, the course, severity, and location of
lesions may vary. EB is a result of abnormal connection between the epidermis and
dermis. The epidermis, which is the most superficial layer of the skin, constitutes an
important barrier between the body and its external environment. The epidermis
prevents the loss of water and protects the body against ultraviolet radiation and
pathogens. The dermis contains blood vessels, nerve endings, and skin appendages.
Under normal conditions, the epidermis and dermis are tightly connected via
protein molecules [1–6].
2. The epidermis – structure and functions
The epidermis is the outermost part of the skin and serves as a barrier protecting
the body against pathogens, ultraviolet radiation, and excessive loss of water. The
epidermal layers, listed from the deepest to the most superficial, include the basal,
spinous, granular, and cornified layers. The basal layer is composed of
keratinocytes, which undergo intense cell divisions. The newly formed cells differ-
entiate as they progress towards the epidermal surface, eventually becoming dead,
anuclear cells (corneocytes) that have no mitochondria. Since they are surrounded
by a lipid layer, corneocytes form an impermeable barrier. The epidermis is strongly
and permanently connected to the dermis via a cytoskeleton and hemidesmosomes.
(Figure 1) [7–9].
The course of EB may be severe if the condition is due to a lack of key adhesion
proteins, for example as a result of loss-of-function mutations in laminin 332 or
collagen VII genes. Conversely, isolated amino acid substitutions typically lead to a
mild fragility of the skin. The genetic and allelic heterogeneity of EB is due to
Figure 1.
Skin structure. (from private sources MN).
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pathological gene variants in 20 different genes. The genes associated with EB
encode intracellular, transmembrane, or extracellular proteins that constitute
structural components of the cytoskeleton (keratin 5 and 14), extracellular matrix
(integrin α6β4, collagen XVII, laminin 332, collagen VII, α3 integrin, kindlin-1),
or intercellular adhesions (desmoplakin, plakophilin, plakoglobin).
3. Epidermolysis Bullosa
The key clinical manifestation of EB is a tendency to develop skin lesions in
response to mechanical stimuli, even those of a very low magnitude. The most
common lesion types include blisters, milia, pigmented lesions, erosions, epidermal
defects, and scars. Other characteristic features of the condition are nail plate
changes, ranging from dystrophy to a complete loss. Another common symptom is
hair loss and—in severe cases—alopecia. Blisters, erosions, and scars developing
near joints may result in contractures and tissue adhesions due to scarring. The
lesions that develop on hands and feet (which are most prone to mechanical inju-
ries) may result in pseudosyndactyly. Contractures exacerbate hand and foot
deformities, leading to disability (“cocoon hand”, or “mitten hand” deformities).
Figure 2.
Ultrastructural sites of blister formation in major forms of epidermolysis bullosa EB. 1. In intact skin, the
ultrastructural regions of the epidermal basement membrane zone consist of basal keratinocytes and the
hemodesmosomal plaque, the lamina lucida, the lamina densa, the upper papillary dermis 2. in eb simplex
(EBS), blisters arise within the lower portion of basal keratinocytes 3. In junctional EB (JEB) blisters form
within the lamina lucida 4. In dystrophic EB (DEB), blisters develop below the lamina densa. Anchoring fibris
are reduced in number in dominant DEB (DDEB) and absent or rudimentary in recessive DEB (RDEB).
KRT5,KRT14 and keratin 5 and keratin14 respectively (s. https://plasticsurgerykey.com/epidermolysis-b
ullosa/).
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Severe forms of EB additionally involve internal anomalies in the oral cavity,
esophagus, trachea, lungs, urinary catheter, or urinary bladder. Intestinal tract
erosions, ulcerations, and scarring lead to strictures, which may result in difficulty
swallowing (dysphagia) and necessitate a feeding jenunostomy to provide enteral
nutrition. Oral manifestations of EB may include the tongue adhering to the floor of
the mouth (ankyloglossia); a narrowed oral opening (microstomia); and difficulties
in chewing and swallowing, which result in malnourishment, osteopenia, osteopo-
rosis, growth retardation, and eating disorders, leading to cachexia. Oral lesions
may cause oral hygiene problems, which leads to caries. Perianal erosions and
ulcerations cause severe pain during defecation, which contributes to constipation.
Possible ocular manifestations involve marginal blepharitis, eyelash loss, ectropion,
adhesions between the palpebral and bulbar conjunctivae (symblepharon), and
corneal blistering, which may lead to blindness. Other manifestations include
treatment-refractory anemia, iron deficiency, and hypoalbuminemia. Due to
chronic ulcerations and an impaired protective function of the epidermis, EB
patients may develop skin cancer (squamous cell carcinoma [SCC]) in their thirties
or forties (Figure 2) [10–15].
3.1 Classification
EB is a result of mutations in approximately 20 genes that encode structural and
enzymatic proteins responsible for forming and maintaining the connections
between the epidermis and dermis. The most common mutations occur in one of
three genes: KRT5, KRT14, or TGM5.
• KRT5: The protein encoded by this gene is a member of the keratin gene
family. The type II cytokeratins consist of basic or neutral proteins which are
arranged in pairs of heterotypic keratin chains coexpressed during
differentiation of simple and stratified epithelial tissues. This type II
cytokeratin is specifically expressed in the basal layer of the epidermis with
family member KRT14. Mutations in these genes have been associated with a
complex of diseases termed epidermolysis bullosa simplex. The type II
cytokeratins are clustered in a region of chromosome 12q12-q13. (RefSeq,
Jul 2008)
• KRT14: This gene product, a type I keratin. At least one pseudogene has been
identified at 17p12-p11.
• TGM5: This gene encodes a member of the transglutaminase family. The
encoded protein catalyzes formation of protein cross-links between glutamine
and lysine residues, often resulting in stabilization of protein assemblies.
This reaction is calcium dependent. Mutations in this gene have been
associated with acral peeling skin syndrome (RefSeq, Oct 2009). [https://www.
genecards.org/]
EB can be classified into three main types, which can be further divided into
subtypes. This classification is based on anomalies in various protein molecules and
each of the resulting EB types has a different clinical course.
• simple epidermolysis bullosa (SEB) involves epidermal anomalies




• dystrophic epidermolysis bullosa (DEB) involves anomalies of the dermis
The diagnosis is made based on a thorough microscopic examination of a skin
sample. The examination helps determine the exact layer of the skin where tissue
separation causes blister formation. There are several layers that can be identified
under a microscope in a skin cross-section. If the blisters form within the epidermis,
the patient is diagnosed with SEB; if they form within the lamina lucida, the patient
is diagnosed with JEB, and if they form just underneath the lamina densa, the
patient is diagnosed with DEB (Table 1).
Overview of EB classification
Subtype Phenotype Inheritance Gene affected
EB simplex — Intraepidermal
EB simplex, localized Palmoplantar blistering from birth or
early infancy, with subsequent
keratoderma in affected areas
AD KRT5 or KRT14
EB simplex, severe Early generalized blistering at or soon
after birth; congenital areas of
denuded skin may be present; can be
life threatening in first year of life;
classically, tense clustered
‘herpetiform’ blisters arise with




AD KRT5 or KRT14
EB simplex,
intermediate
Generalized, although less severe
blistering than EB simplex, severe
AD KRT5 or KRT14
EB simplex with
mottled pigmentation
Blistering from birth of intermediate
severity; additional mottled or
reticulate macular pigmentation
typically of the neck, upper trunk and







Vesicles from birth, on a background
of inflammatory migratory circinate







Marked erosions in limbs at birth,




alopecia has occasionally been
reported; dilated cardiomyopathy





Autosomal dominant disease is mild
with mainly acral blistering; autosomal
recessive has an intermediate
presentation




Generalized blistering with variable-
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Overview of EB classification
Subtype Phenotype Inheritance Gene affected
keratoderma and nail dystrophy;
mucosal involvement is common;




More severe, widespread generalized
blistering or loss of skin at birth with
pyloric atresia; early mortality within






or severe; keratin 5 abnormalities
tend to have a more severe
phenotype; absence of keratin 5
associated with widespread skin
disease and early mortality;
improvement of blistering with age is
not expected












and skin fragility; mild mottled





Early blistering, with pretibial
predominance; poikiloderma may be





Junctional EB, severe Blistering may be mild at birth and
localized to periungual, buttock and
elbow regions; overgranulation
develops, particularly on orofacial
and periungual regions, with
development of bulbous nail folds;
alopecia is common; dental enamel
defects are usual; a hoarse cry is often
a feature; usually fatal within the first





Less severe than above, with a
reduced tendency to develop
exuberant granulation tissue;






Extensive areas of skin loss seen at
birth with severe cutaneous fragility;
early-onset pyloric atresia, a frequent
cause of early mortality, within days
or weeks of birth; duodenal and anal
atresia may also feature; milder non-
lethal variants often show
genitourinary involvement
AR ITGA6 and ITG84
Junctional EB,
localized
Limited cutaneous fragility, often








Overview of EB classification
Subtype Phenotype Inheritance Gene affected
Junctional EB, inversa Flexural blistering from birth; dental





Onset in childhood, with often acral
fragility; skin fragility is progressive
and loss of dermatoglyphs may be
seen owing to scarring; variable






Skin fragility from birth with marked
exuberant granulation tissue (greater
than that in junctional EB, severe),
particularly on face and neck; nail
dystrophy and loss with granulation
tissue of nail beds; laryngeal
granulation can lead to respiratory
compromise and death; conjunctival








Variable degree of cutaneous
involvement; fatality in early
childhood is common; nail dystrophy
possible; hair loss may occur
AR IGTA3
Dystrophic EB — sublamina densa
Intermediate DDEB1 Generalized skin fragility, scarring
and milia presenting from birth or
early infancy, with prominence over
acral sites, elbows and knees;
involvement of the mucous
membranes may lead to microstomia,
ankyloglossia and oesophageal
stenosis, although less commonly
than in severe RDEB
AD COL7A1
Localized DDEB1 Predominantly acral blistering,
scarring and milia seen from birth or
early infancy; occasional nails-only
presentation, with progressive
dystrophy and eventual nail loss;
rarely, cutaneous features may
predominate over pretibial skin alone
(and can present as late-onset
disease)
AD COL7A1
DDEB, pruriginosa1 Profoundly pruritic linear cords of
papules associated with fragility,
scarring and milia on the shins, and
occasionally progressing to arms; may
present in childhood or adulthood;




Blistering evident at or shortly after
birth, usually on extremities where
there may be aplasia cutis, whilst
scarring and milia may occur;
spontaneous resolution of cutaneous
fragility within the first 2 years of life
AD COL7A1
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Overview of EB classification
Subtype Phenotype Inheritance Gene affected
Intermediate RDEB3 Phenotype similar to that of
intermediate DDEB, although greater
severity with flexion contractures,
limited digital fusion and occasional
striate keratoderma
AR COL7A1
Severe RDEB3 Widespread blistering from birth,
with extensive scarring and
development of microstomia,
ankyloglossia, oesophageal stenosis,
flexion contractures of limbs and
pseudosyndactyly; nails are often lost
early in disease course; high risk of
cutaneous SCC arising in EB wounds.
AR COL7A1
RDEB, inversa3 Generalized blistering from birth, of
intermediate severity; subsequently,
fragility tends to be displayed on
flexural sites
AR COL7A1
RDEB, localized3 Skin fragility and blistering typically
at birth or neonatal period, limited to
acral sites such as hands and feet, or
occasionally only to pretibial skin,
where it may manifest as late-onset
disease during adulthood; nail
dystrophy and loss usual
AR COL7A1
RDEB, pruriginosa3 As for DDEB, pruriginosa AR COL7A1
RDEB, self-
improving3
As for DDEB, self-improving AR COL7A1
DEB, severe4 Clinically indistinguishable from
severe RDEB, with severe






Kindler EB — variable and mixed
None Generalized blistering and variable
photosensitivity from birth or early
childhood, with mucosal fragility;
blistering gives way to progressive
poikiloderma, initially most marked
over dorsal hands and neck;
confluent palmoplantar keratoderma
and adermatoglyphia may occur;
gingivitis and dental disease is a
feature; oesophageal narrowing and
colitis has been reported;
mucocutaneous SCC has been
reported, with poor prognosis
AR FERMT1
AD, autosomal dominant; AR, autosomal recessive; DDEB, dominant dystrophic epidermolysis bullosa; DEB;
dystrophic epidermolysis bullosa; EB, epidermolysis bullosa; EM, electron microscopy; ER, endoplasmic reticulum;
RDEB, recessive dystrophic epidermolysis bullosa; SCC, squamous cell carcinoma. 1Major type is DDEB. 2Previously
known as transient bullous dermolysis of the newborn baby. 3Major type is RDEB. 4Major type is DEB (dominant
and recessive compound heterotygosity). Adapted from consensus guidelines3.
Table 1.




SEB primarily shows an autosomal dominant pattern of inheritance, with the
most common mutations in genes KRT5 and KRT14. Autosomal recessive inheri-
tance is less common and caused by mutations in genes KRT14, ITGA6, ITGB4 (this
genes encodes a member of the integrin alpha chain family of proteins. Integrins are
heterodimeric integral membrane proteins composed of an alpha chain and a beta chain
that function in cell surface adhesion and signaling. The encoded preproprotein is pro-
teolytically processed to generate light and heavy chains that comprise the alpha 6
subunit. This subunit may associate with a beta 1 or beta 4 subunit to form an integrin
that interacts with extracellular matrix proteins including members of the laminin
family. The alpha 6 beta 4 integrin may promote tumorigenesis, while the alpha 6 beta 1
integrin may negatively regulate erbB2/HER2 signaling. Alternative splicing results in
multiple transcript variants. [provided by RefSeq, Oct 2015]).
DSP (This gene encodes a protein that anchors intermediate filaments to des-
mosomal plaques and forms an obligate component of functional desmosomes), or
PKP1 (Plakophilin proteins contain numerous armadillo repeats, localize to cell desmo-
somes and nuclei, and participate in linking cadherins to intermediate filaments in the
cytoskeleton. This protein may be involved in molecular recruitment and stabilization
during desmosome formation). SEB caused by a PLEC1(Plakins, with their multi-
domain structure and enormous size, not only play crucial roles in maintaining cell and
tissue integrity and orchestrating dynamic changes in cytoarchitecture and cell shape, but
also serve as scaffolding platforms for the assembly, positioning, and regulation of signal-
ing complexes (reviewed in PMID: 9701547, 11854008, and 17499243) mutation may
show an autosomal recessive or autosomal dominant pattern of inheritance.
JEB is primarily caused by mutations in genes LAMB3, LAMC2, LAMA3 (this
genes is a laminin that belongs to a family of basement membrane proteins), COL17A1
(This gen encode collagen XVII is a structural component of hemidesmosomes,
multiprotein complexes at the dermal-epidermal basement membrane zone that mediate
adhesion of keratinocytes to the underlying membrane), ITGA6 or ITGB4 and is char-
acterized by autosomal recessive inheritance. A recent study (2009) showed a
possible autosomal dominant inheritance pattern in the case of a mutated COL17A1.
DEB is caused by mutations in only one gene, COLA1. The location and type of
mutation determine the inheritance pattern (autosomal recessive or dominant).
3.3 SEB subtypes
• Koebner type: mutated genes for keratin 5 and 4 (KRT5, KRT4); lesions are
often present at birth or in infancy; characteristic features are hyperkeratotic
lesions, hemorrhagic bullae, and erosions.
• Dowling-Meara type: mutated KRT14 and KRT5 genes, which encode keratin
14 and 5, respectively; autosomal dominant inheritance; lesions are located
primarily on the feet, less commonly in other locations; a relatively mild
course.
• Weber-Cockayne type: associated with mutated KRT5 (region 12q13.13) and
KRT14 (region 17q21.2) genes; characterized by a severe course and
herpetiform blisters. Poorly healing blisters and erosions lead to scarring and
contractures.
• SEB with muscular dystrophy: a mutated plectin-encoding PLEC1 gene.
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3.4 JEB subtypes
• JEB with pyloric atresia: this rare type of EB results from mutated ITGB4 and
ITGA6 genes that encode α6 β4 integrin. Skin lesions are accompanied by
esophageal, pyloric, and/or duodenal atresia. Enamel hypoplasia is common.
• Herlitz type: mutations in the LAMA3, LAMB3, and LAMC2 genes, which
encode the polypeptide subunits of laminin 5 (α-3, β-3, and γ-2, respectively).
Fatal type of EB, characterized by blisters and erosions over the entire body,
which causes multiple infections that may lead to sepsis, loss of proteins
(malnourishment), scarring, contractures, defects of large areas of skin.
• Non-Herlitz type: mutations in genes COL17A1, LAMB3, LAMC2, or LAMA3
encoding laminin 5 and collagen XVII.
3.5 DEB subtypes
• Hallopeau-Siemens type: a mutated COL7A1 gene, which encodes collagen VII.
This type of EB is characterized by scarring, erosions, pseudosyndactyly of the
hands and feet; nail plate involvement, esophageal atresia, and corneal ulcers
are common.
• non-Hallopeau-Siemens type: mutated COL7A1 gene, encoding collagen VII.
• Cockayne-Toureine type: autosomal dominant inheritance; mutated COL7A1
(collagen VII); skin lesion on the limbs.
• Pasini type: possible nail plate involvement; oral and mucosal lesions.
3.6 Diagnostic investigations
A primary diagnosis of EB is based on the clinical presentation. The definitive
diagnosis is established after skin samples are examined via immunofluorescence
antigen mapping and transmission microscopy.
Diagnosis is confirmed via genetic analysis that determines the type of mutation.
3.7 Differential diagnoses
The differential diagnoses should include congenital dermatoses, herpes simplex
virus infections, epidermolytic hyperkeratosis with erosions and blisters, staphylo-
coccal scalded skin syndrome, bullous pemphigoid, neonatal pemphigoid, and
gestational pemphigoid.
3.8 Treatment
Management is primarily symptomatic. Surgical treatment mainly involves skin
grafting. Importantly, the use of autologous skin grafts is ineffective due to poor
healing and chronic wound formation at the donor sites. Plastic surgery procedures
play an important role in repairing contractures and pseudosyndactyly of the hands
and feet. In the case of esophageal, pyloric or duodenal atresia, various surgical
procedures are used to overcome the effects of gastrointestinal strictures (e.g.
feeding jejunostomy, endoscopic balloon dilatation).
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EB management involves primarily local care of chronic wounds, ulcers, ero-
sions, and blisters. Treatment challenges involve frequent bacterial infections, due
to their chronic character, and factors that inhibit healing, such as malnutrition,
anemia, itching, or repetitive wound irritation with regular dressing changes, all of
which disturb epithelialization. Moreover, wounds may cause severe pain, exacer-
bated by regular, frequent dressing changes. Importantly, the condition requires
life-long care, with the cost of monthly treatment often exceeding several hundred
dollars. Therefore, the process of selecting the optimal dressing should include the
following parameters: the price, availability, effectiveness, and safety. Other
important complementary treatments include physiotherapy, genetic counselling,
aggressive treatment of infections, nutritional supplementation, and skin cancer
monitoring [17–31].
Despite the enormous advances in our understanding of molecular genetics and
EB physiopathology that have taken place over the last several decades, a definitive
cure is yet to be discovered. There are many ongoing studies aiming to develop an
effective treatment. These studies focus on several potential lines of treatment,
including disease modifying treatments to diminish disease severity. Gene thera-
pies, bone marrow transplants, and tissue engineering are receiving the most
attention.
Advanced therapy medicinal products (ATMPs) are medicines for human use
that are based on genes, tissues or cells. They offer groundbreaking new opportu-
nities for the treatment of disease and injury. ATMPs can be classified into three
main types: gene therapy medicines, somatic-cell therapy medicines, tissue-
engineered medicines. In addition, some ATMPs may contain one or more medical
devices as an integral part of the medicine, which are referred to as combined
ATMPs. An example of this is cells embedded in a biodegradable matrix or scaffold.
Gene therapy involves cultures of keratinocytes (obtained from patients with
recessive DEB [RDEB]) that have been transduced with a retroviral vector
containing full-length cDNA of the COL7A1 gene (for collagen VII). These cultures
are, subsequently, placed onto the patient’s wounds in the form of epidermal
grafts [32]. Treatment efficacy and collagen VII expression were demonstrated;
however, the response lasted up to 12 months. Nonetheless this therapy is safe.
One disadvantage of this method is the fact that it can be used in limited areas
(at chronic wound sites). This method has been also used in a patient with JEB, in
whom the placement of genetically corrected keratinocytes onto chronic wound
sites led to successful wound healing. Based on the available reports, gene therapies
are promising treatment modalities with a potential therapeutic effect in
genodermatoses.
Bone marrow transplant (BMT) and allogenic stem cell transplantation
(ASCT) are other very promising treatment strategies. In 2010, Wagner et al.
performed ASCT in children with RDEB. Although the patients were not completely
cured, their skin blisters were reduced, and skin regeneration was accelerated. BMT
in RDEB patients has been reported to improve the clinical status, despite the lack
of collagen VII growth in the skin. BMT is an experimental therapy, which is used as
part of clinical studies, and currently is not an approved treatment. The risk of
death and the uncertain degree and mechanism of the clinical response should be
viewed in light of the results of the most recent translational research in RDEB,
which reports ASCT to be currently the only therapeutic approach that shows
systemic effects in what essentially is a systemic disease. There is a clear need for
reports presenting data from extensive clinical studies to establish guidelines and
warnings for the use of ASCT in EB treatment.
As pluripotent cells, MSCs have a potential to differentiate into many different
types of skin cells, including keratinocytes, endothelial cells, and monocytes. Due to
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their immunomodulatory and anti-inflammatory effects, MSCs may play a signifi-
cant role in wound healing and tissue regeneration. Moreover, MSCs do not trigger
an immune response in the recipient, hence there is no need to match the donor’s
and recipient’s human leukocyte antigen (HLA) types [33]. Due to their multi-
directional differentiation potential, MSCs have been shown to regenerate collagen
VII, which has a beneficial effect on the healing of wounds (including chronic
wounds) and improves skin stability. These effects were observed with intradermal
administration, which—apart from presenting fewer challenges—does not require
as many MSCs as intravenous administration. Most studies have focused on bone
marrow-derived MSCs (BM-MSCs). However, their harvesting from the bone mar-
row is a relatively invasive procedure. Moreover, the multipotent differentiation
potential of BM-MSCs diminishes with age. Therefore, MSCs are currently obtained
from alternative sources, such as the umbilical cord [34], which can provide up to a
billion cells in 30 days, obtained non-invasively. The umbilical cord consists of
umbilical vessels surrounded by a connective tissue, referred to as Wharton jelly
(WJ). WJ-derived MSCs have a higher proliferative potential and are more homo-
geneous than those derived from the bone marrow. WJ-MSCs are similar to BM-
MSCs in their fibroblast-like phenotype, non-hematopoietic surface markers [35],
low immunogenicity [36], multipotent plasticity, and the expression of CD90,
CD73, CD105 markers [37]. Moreover, WJ-MSCs seem to have more pronounced
pro-angiogenic properties than BM-MSCs; they promote neovascularization and
perfusion by releasing paracrine factors and by playing the role of perivascular
precursor cells [38]. WJ-MSCs are a highly efficient source of young, non-
carcinogenic, and non-immunomodulatory cells [39]. All these properties and the
fact that WJ-MSCs are easily available make these cells a promising strategy for
treating wounds in EB patients.
Sebastiano et al. propose an innovating cell therapy for RDEB treatment, by
developing a state of the art protocol of genetically repaired induced pluripotent
stem cells (iPSCs) as to generate sheets of normal skin tissue to treat affected skin
areas [40]. Moreover, as numerous stem cells are needed in order to cover the
affected surface area, authors outline the necessity for creating personalized iPSCs
banks as to provide a constant long-term iPSCs source. Generally, human iPSCs can
be generated by reprogramming differentiated somatic cells into pluripotent
embryonic stem cells (ESCs) capable of differentiating into ectoderm, mesoderm or
endoderm cells. Reprogramming involves the introduction of a known set of genes
into the somatic cells, using integrating viral and non-integrating non-viral
methods. Following successful reprogramming, somatic cells will express genes and
surface proteins similar to ESCs in vitro and will be able to differentiate into any of
the three embryonic germ layers.
Tissue engineering: Not unlike patients with extensive burns, patients with EB
do not qualify for autologous skin grafts. One solution available to these patients
involves the use of allogeneic grafts, which serve to temporarily cover the wound
(after 7 days the graft is rejected by the recipient; [41]). Therefore, tissue engineer-
ing seems to be a promising solution, as it helps create biopolymer scaffolds to cover
the wounds. The idea is to create skin substitutes, which can then be seeded with
keratinocytes, fibroblasts, or stem cells. Such polymer materials constitute a micro-
environment and provide adequate scaffolds for cell colonization and epithelial cell
migration during wound epithelialization. The multi-disciplinary nature of tissue
engineering has helped develop many bioengineered skin substitutes, with potential
applications as a suitable dressing for treating refractory wounds, such as those in
EB patients. The field of tissue engineering has been rapidly transferring from
the realm of basic research to commercial applications. There are many in
12
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vitro-generated skin substitutes. They are available in various forms, which include
epidermal, dermal, and dermo-epidermal analogs or complex skin analogs, and can
be composed of cellular or acellular scaffolds [42–51].
High-quality, safe skin analogs should be cost-effective, biocompatible, biode-
gradable, and noncarcinogenic, carry no risk of infectious disease transfer, and
provoke no activation of the recipient’s immune system. Despite a whole spectrum
of bioengineered products currently available on the market, there are scarcely any
that meet all the requirements of natural skin. Natural skin is composed of the
epidermis, dermis, and subcutaneous tissue. It contains appendages, such as sweat
glands, nails, and hair, as well as nerve endings and blood vessels. Additionally,
natural skin protects the body against the external environment via its thermoreg-
ulatory function and its role in maintaining water–electrolyte balance. It also
facilitates the perception of pain, heat, and touch; manufactures vitamin D; and
shields the body against ultraviolet radiation by the means of melanin-producing
melanocytes responsible for skin pigmentation [52, 53]. Due to the wide range of
functions performed by human skin, creating its analog is a challenge for tissue
engineers.
The first product that has transferred the potential of bioengineering into real-
life EB applications is an autologous cultured epidermal substitute (CES). The
pioneering study by Rheinwald and Green demonstrated that epidermal
keratinocytes from a single-cell suspension can be cultured in the form of sheets,
and the resulting multi-layered sheets have proven to be very effective in the
treatment of burns and wounds in EB patients. There are many commercially
available skin substitutes composed of both epidermal and dermal components. Bell
et al. developed a cultured skin substitute (CSS) (an equivalent of living skin)
composed of keratinocytes and fibroblasts in a collagen gel. Boyce and Hansbrough
developed a CSS composed of a collagen-glycosaminoglycan composite scaffold
populated with keratinocytes and fibroblasts. Kuroyanagi et al. developed another
CSS, composed of a spongy collagen matrix with keratinocytes and fibroblasts. Such
two-layered CSSs are intended to permanently cover full-thickness skin defects.
There have been studies on wound healing in EB with the use of OrCelTM,
Biobrane, and Apligraf dressings. OrCelTM is a bilayer dressing composed of a
bovine-collagen I matrix populated with neonatal foreskin keratinocytes and fibro-
blasts [54–56]. Despite the fact that OrCelTM exhibits beneficial wound healing
properties in RDEB patients—via cytokines and growth factors, such as tumor
growth factor alpha (TGFα), fibroblast growth factor 1 (FGF-1), and keratinocyte
growth factor 1 (KGF-1)—its bovine collagen component increases the risk of graft
rejection and transfer of diseases to the donor [57]. Another bilayer skin substitute
is Biobrane, which is composed of a 3D nylon fiber scaffold and an ultrathin
semipermeable epidermis-mimicking silicone layer that controls fluid loss [56–59].
The nylon fibers are surrounded by porcine collagen type 1. Jutkiewicz and
Noszczyk [60] were the first to report the use of Biobrane in the postoperative hand
care in a group of RDEB patients. Apligraf is another bilayer skin substitute com-
posed of dermal and epidermal analogs. The epidermal and dermal layers contain
cultured keratinocytes and neonatal foreskin fibroblasts. The dermal layer addi-
tionally contains bovine collagen type 1, which facilitates cell growth and differen-
tiation. Apligraf has a short life span, and its use is associated with high costs [57].
Nonetheless, this dressing was reported to be effective in treating EB wounds
[61, 62].
Safe and Effective Therapy in the Light of Clinical Trials - New Approach to
Treatment by Innovative Method (BIOOPA-ATMP) grant no. STRATERMED2/
269807/14/NCBR/2015.
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Alternative promising product for the treatment of chronic wounds that occur in
EB and other genodermatoses, as well as in burns, is an allogeneic, acellular human
skin equivalent sterilized with radiation, and seeded with Wharton's jelly-derived
mesenchymal stem cells- WJ-MSCs about the acronym in polish BIOOPA (biologi-
cal dressing) is an advanced therapy medicinal product composed of a
decellularized matrix of the superficial layers of cadaveric human skin
(10 cm  10 cm). Acellular dermal matrix (ADM) is a Chemically/enzymatically
processed allograft. This processing removes all epidermal and dermal cells while
preserving the molecular and physiological structure of collagen fibers. The scaffold
is sterilized via radiation and then seeded with 30 million WJ-MSCs. As a result of
decellularization, this skin substitute does not induce an immune response in the
recipient and poses a lower risk of transmitting any diseases. In order to assess the
safety and efficacy of the BIOOPA dressing, the relevant study was conducted in
two stages. During the first stage, in vitro experiments showed BIOOPA viability.
All examination techniques demonstrated graft infiltration by host cells and
neovascularization of the biological dressing. Moreover, BIOOPA is characterized
by low immunogenicity, which was confirmed in histopathology examinations and
in vitro T-cell proliferation tests. The second stage of the study was conducted in a
group of qualified volunteers with EB and approved by an ethics committee. The 6-
month follow-up indicates the safety and efficacy of the BIOOPA dressing, with no
infections or necrosis at the graft implantation site observed over the follow-up
period. The subjects reported decreased pain and improved quality of life
Figures 3–8 [63, 64].
Figure 3.





Day 0, procedure: chronic wound in the knee area covered with prepared graft in the 20-years old patient with
EB (allogenic,acellular, human skin equivalent).
Figure 5.
Bioopa dressing: The scaffold is seeded with 30 million WJ-MSCs in 5 mL of a 5% human albumin solution
covered with chlorhexidine-impregnated dressings and collagen gel. The same 20-years old patient with EB
(chronic wound in the knee area).
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Figure 7.
Hematoxylin and eosin stain of scaffold populated with mesenchymal cells fromWharton’s jelly. After 72 hours
of culture mesenchymal stem cells create a multilayer structure on the scaffold resembling human epithelium.
Figure 6.
Results after 30-day follow-up in this patient with EB: All examination techniques revealed host-cell
infiltration and neovascularization of the biological dressing. They are characterized by low immunogenicity, as




To date, there is no causative treatment of EB, despite multiple ongoing studies
involving gene therapy and bone marrow transplantation. The standard of EB
management still involves symptomatic conservative treatment. There is immense
hope in therapies with the use of stem cells of various origins (bone marrow,
umbilical cord, etc.). Advanced applications of various types of cells (embryonic,
prenatal, and adult stem cells, endothelial cells, and melanocytes) and the rapid
development of biomedical engineering, which contributes to refining biocompati-
ble materials, such as collagen, hyaluronic acid, elastin, polylactic acid (PLA), poly
lactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG), bring hope of
effective treatment for chronic wounds of various origin. The most recent develop-
ments allow for the manufacture of progressively better skin substitutes, which in
the future may exhibit the fundamental characteristics of natural human skin
(including sweat glands and hair follicles), more homogeneous pigmentation, and
allow for the healing of scars [65]. Thus, further studies and efforts are crucial for
creating skin substitutes truly mimicking natural skin. Despite the enormous pro-
gress in the treatment of EB, the current treatments are clearly not a definitive cure
for this debilitating disease, and the risk associated with some of these procedures
must be weighed against their potential benefits. Effective treatment of this, cur-
rently incurable, group of diseases requires advanced and innovative strategies with
an improved safety profile, such as the ones that are currently being developed
[66–77].
The BiOOPA dressing is easily available, safe, and relatively inexpensive, all of
which make it a promising therapy for EB-associated wounds. Preliminary results of
the BIOOPA study indicate the dressing to be safe and effective to improve the
quality of life in study subjects. Currently BIOOPA is evaluated as part of a phase
Figure 8.
Laser scanning confocal microscopic study using second-harmonic generation technique reveals the structure of
collagen fibrils in acellular dermal matrix after decellularization and X-ray radiation 35 kG (Bar 1/4
50 mm).
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I/II clinical study during the second year of observation. Our preliminary results of
clinical trial strongly suggest, that our innovative dressing is a promising strategy
and a tool for clinicians in the search for new opportunities of treatment for this rare
condition.
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